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ABSTRACT: An increasing number of macrocyclic peptides that cross biological membranes 
are being reported, suggesting that it might be possible to develop peptides into orally 
bioavailable therapeutics; however, current understanding of what makes macrocyclic peptides 
cell permeable is still limited. Here, we synthesized 62 cyclic hexapeptides and characterized 
their permeability using in vitro assays commonly used to predict in vivo absorption rates, i.e. the 
Caco-2 and PAMPA assays. We correlated permeability with experimentally measured 
parameters of peptide conformation obtained using rapid methods based on chromatography and 
nuclear magnetic resonance spectroscopy. Based on these correlations, we propose a model 
describing the interplay between peptide permeability, lipophilicity and hydrogen bonding 
potential. Specifically, peptides with very high permeability have high lipophilicity and few 
solvent hydrogen bond interactions, whereas peptides with very low permeability have low 
lipophilicity or many solvent interactions. Our model is supported by molecular dynamics 
simulations of the cyclic peptides calculated in explicit solvent, providing a structural basis for 
the observed correlations. This prospective exploration into biomarkers of peptide permeability 
has the potential to unlock wider opportunities for development of peptides into drugs. 
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INTRODUCTION 
Peptides are promising drug leads because of their potential to simultaneously offer the 
advantages of small molecule therapeutics and large protein biologics [1]. Peptides can bind with 
exquisite specificity to their in vivo targets, resulting in exceptionally high potencies and 
relatively few off-target side-effects. Additionally, their small size compared to proteins suggests 
that they might adopt the favorable pharmacological properties that are commonly associated 
with small molecule therapeutics, such as oral bioavailability.  
Achieving high oral bioavailability for peptide drugs is still perceived to be a challenging task 
and is a key design objective in the pharmaceutical industry, especially for chronic treatments. 
This challenge has translated to wide interest in drug design guidelines to help alleviate the often 
huge effort required to develop a successful oral therapy. Principles for designing orally 
bioavailable small molecule therapeutics have been described in the widely referenced 'Lipinski 
Rule of Five' [2]. Other guidelines to assess 'drug-likeness' or 'lead-likeness' have subsequently 
been established [3], which note the importance of polar surface area, among other criteria [4]. 
These guidelines have been most useful in understanding the properties of small molecule 
compounds that are associated with oral bioavailability but have led to the perception that 
peptides make poor drugs because they occupy an unconventional physico-chemical space.  
We envisage that peptide and peptidomimetic macrocycles have the potential to fill a gap in 
the chemical space between small molecules and protein therapeutics and thus emerge as a 
modality for difficult targets. This view is supported by a growing number of peptides that 
appear to be well absorbed within the gastrointestinal tract [5] and examples where cyclic 
peptides have shown orally-delivered bioactivity in animal models of disease, including 
inflammatory pain [6] and neuropathic pain [7]. Interestingly, a common structural feature of 
 4 
these reported peptides is a macrocyclic backbone, which is consistent with a study showing that 
cyclic peptides have improved membrane permeability over their linear counterparts [8]. 
Cyclization is important for oral bioavailability presumably because it improves stability against 
proteolytic degradation and also directs the peptide into specific conformations that might be 
favorable for membrane permeability [8,9]. Arguably the most famous example of a cyclic 
peptide with reasonable oral bioavailability yet poor drug-likeness is cyclosporin A (CSA), 
which was originally discovered from a soil fungus and is now widely used as the 
immunosuppressant cyclosporine [10].  
Backbone N-methylation is another structural feature, aside from cyclization, that seems to be 
correlated with improved membrane permeability [11]. Indeed, N-methylation of a cyclic peptide 
agonist of somatostatin improved its oral bioavailability without significantly modifying its 
biological activity and selectivity [12]. In some cases, N-methylation does not increase 
membrane permeability and arbitrarily increasing the number of N-methyl modifications is not 
reflected by the sought-after increase in permeability [13]. Recently, strategic incorporation of 
N-methyl groups using either an on-resin chemical approach [14] or a structure-informed 
approach has led to the development of cyclic peptides with small molecule-like oral 
bioavailability [15]. In the structure-informed approach, amide temperature coefficients 
measured by NMR were used to identify appropriate amides to modify. Both of these approaches 
recognize the intricate relationship between N-methylation and the role of unmodified amides in 
the formation of intra-molecular and solvent hydrogen bonds. The importance of hydrogen 
bonding potential of cyclic peptides is supported by a recent study [16], where the relative rates 
of diffusion of 11 closely-related cyclic hexapeptides across an artificial membrane were found 
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to correlate with in silico estimates of the solvation free energies associated with their predicted 
aqueous and membrane-associated conformations. 
A key objective of this study was to define the properties that influence permeability of cyclic 
peptides. Here we correlate the in vitro permeability of peptides with their physico-chemical 
properties (Figure 1). We synthesized and purified a library of 62 hexapeptides with varying 
sequence composition and N-methylation content. We focused on convenient and rapid 
experimental techniques to characterize the lipophilicity (e.g. analytical chromatography) and 
hydrogen bonding potential (e.g. NMR amide temperature coefficients) of the peptides. Although 
amide temperature coefficient experiments have been used previously to provide supplementary 
information in structural studies of proteins, their potential as experimental markers of peptide 
permeability has not been studied. Based on these measurements, we developed a model 
describing the interplay between peptide lipophilicity and hydrogen bonding potential that can be 
assessed by experimental means. Our model is supported by molecular dynamics simulations of 
the peptides in explicit solvent, relating our experimentally-derived observations to predicted 
structures. 
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EXPERIMENTAL SECTION 
General. Fmoc-protected amino acids, resins and coupling agents were purchased from 
ChemImpex International. All other reagents were purchased from Auspep, Merck and Sigma, 
and used without further purification. 
Peptide synthesis. Linear peptides were synthesized on 2-chlorotrityl chloride (2CTC)resin. 
Couplings were performed using 4 equiv. Fmoc-protected amino acid, 3 equiv. HATU (O-(7-
azabenzotriazol-1-y1)-N,N,N',N'-tetramethyluroniumhexafluorophosphate) or HCTU (O-(1H-6-
chlorobenzotriazol-1-y1)-N,N,N',N'-tetramethyluro-nium hexafluorophosphate) and 6 equiv. 
N,N-diisopropylethylamine (DIPEA) in dimethylformamide (DMF) for 0.5–2 h. Fmoc 
deprotection was carried out with 30% (v/v) piperidine in DMF. After each coupling and 
deprotection step, the resin was washed with DMF (3×), dichloromethane (DCM) (3×) and DMF 
(3×). Peptides were cleaved from the resin using 1% (v/v) TFA (trifluoroacetic acid) in DCM 
(dichloromethane). Head-to-tail cyclization was performed in DMF with 3 equiv. HATU and 6 
equiv. DIPEA. Following removal of the solvent, side-chain protecting groups were removed in 
94:3:3 TFA/TIPS (triisopropylsilane)/water. After cyclization, the peptides were purified by 
reverse-phase preparative HPLC. Purity of fractions was assessed using ESI-MS and analytical 
HPLC. 
PAMPA for determining passive cell permeability. A 96-well donor and accepter plate 
system pre-loaded with artificial lipid membrane (BD GentestTM Pre-coated PAMPA Plate) was 
used. In these plates, each well consists of a polyvinylidene fluoride (PVDF) filter coated with a 
lipid/oil/lipid trilayer, where the lipid layer is composed of 1,2-dioleoyl-sn-glycero-3-
phosphocholine and the oil layer is composed of hexadecane [17].  
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300 μL of 50 μM peptide (5% (v/v) DMSO in Hank's Balanced Salt Solution [HBSS])was 
added to the donor wells and 200 μL of buffer (5% (v/v) DMSO in HBSS) was added in the 
acceptor wells. The acceptor plate was lowered onto the donor plate so that the artificial 
membrane was in contact with the peptide solution below. A cover plate was placed on the 
acceptor plate and the assay plate covered with foil. Incubation of peptides was carried out at 
room temperature for 5 h. 
Acceptor and donor well concentrations were measured using an UHPLC/MS system 
equipped with a C18 Kinetex (2.10 x 50 mm, 7 μm). The eluent was acetonitrile/water 10/90 
with 0.045% v/v formic acid and was pumped through the column at 0.4 ml min-1. The visible 
spectra were recorded at 214 and 280 nm. Mass spectrometer parameters were set as follows for 
positive ion mode: gas temperature 250°C; drying gas (N2), 15 L min-1; capillary voltage 4.5 kV. 
The mass range used for selective ion monitoring was changed depending on the peptide.  
As the concentration differences between acceptor and donor wells are significant, they were 
analyzed separately. Dilution series of each peptide sample were prepared and injected into the 
LC-MS to generate a standard curve for quantification. Five μL from donor or 40 μL from 
acceptor wells were injected into the LC-MS and the analyte peak areas were recorded. The limit 
of detection of the peptides varies; however, most gave a value of ~0.05 μM. Percentage 
permeability was calculated relative to the equilibrium concentration.  
The permeability coefficient (Papp-pampa) values were calculated according to the equation: 
𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎−𝑎𝑎𝑎𝑎𝑝𝑝𝑎𝑎𝑎𝑎 = − ln�1 − 𝐶𝐶𝐴𝐴/𝐶𝐶𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑝𝑝�𝐴𝐴 × (1 𝑉𝑉𝐷𝐷 + 1 𝑉𝑉𝐴𝐴) × 𝑡𝑡⁄⁄  
Where CA is the sampled concentration in the acceptor compartment, VA is the volume in the 
acceptor compartment, VD is the volume of the donor compartment, t is the incubation time, A is 
the area of the filter and: 
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𝐶𝐶𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑝𝑝 = [𝐶𝐶𝐷𝐷 × 𝑉𝑉𝐷𝐷 + 𝐶𝐶𝐴𝐴 × 𝑉𝑉𝐴𝐴]/(𝑉𝑉𝐷𝐷 + 𝑉𝑉𝐴𝐴) 
Each PAMPA measurement was typically an average of triplicates and repeated to n = 3. For 
some peptides with low permeability (e.g. Papp-pampa < 0.1 x 10-6 cm/s), measurements were not 
repeated more than n = 2. Permeability values could not be determined for peptides 29, 30, 31, 
and 46 due to poor sample solubility. 
Caco-2 permeability studies. Caco-2 cells were cultured in an atmosphere of 5% CO2 and 
90% relative humidity in T75 flasks (Nunc) with 10 mL of media (10% fetal bovine serum 
(FBS), 1% non-essential amino acids (NEAA), 1% penicillin/streptomyocin). Cells were 
passaged 1:10 every five days, or when 80-90% confluent, using 0.25% trypsin-EDTA 
(Invitrogen, Gibco Laboratories). Caco-2 cells were seeded onto each membrane of the transwell 
permeable support 12-well plate insert to give 50,000 cells/well. The individual feeding tray 
wells received 1.5 mL of cell culture medium. The cell culture medium was changed every 
second day. Caco-2 cell monolayers were used for experimentation 21 days post-seeding. To 
prepare the cells for transport studies (apical to basolateral, A to B) cell culture media was 
removed from both compartments and the cells were washed once with HBSS in both the A and 
B compartments. The washing buffer was removed and 0.75 mL of fresh HBSS placed in 
compartment A and 1.5 mL of HBSS in compartment B for pre-incubation, carried out at 37°C 
for 30 min under agitation. Transepithelial electrical resistance (TEER) was measured across the 
cell membranes at the beginning of the experiment. HBSS was subsequently removed from 
compartment A, replaced with 0.75 mL of the peptide solution prepared in HBSS. Monolayers 
were incubated and continuously shaken. 100 µL samples were taken from the A and B 
compartments at 45 min and 90 min intervals, and the buffer volume replenished. After 90 min, 
200 µL of compartment A and B was also collected for Lucifer Yellow (LY) measurements. 
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Amount of LY permeated was measure on a Tecan plate reader (excitation 485 nm, emission 530 
nm). At the conclusion of the experiment TEER was measured again to confirm the integrity of 
the Caco-2 monolayers (TEER >300 Ω cm2). Acceptor and donor well concentrations were 
measured by LC-MS as per the PAMPA Assay. 
The permeability coefficient (Papp-caco) values were calculated according to the equation: 
𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎−𝑐𝑐𝑎𝑎𝑐𝑐𝑐𝑐 = 𝑉𝑉𝐴𝐴𝑡𝑡 × 𝐶𝐶𝐴𝐴𝐶𝐶0 × 1𝐴𝐴 
Where CA is the sampled concentration in the acceptor compartment, VA is the volume in the 
acceptor compartment, t is the incubation time, C0 is the initial concentration in the donor 
compartment, and A is the area of the filter of the transwell plate. Each Caco-2 measurement was 
typically an average of triplicates and repeated to n = 3. For permeability values less than 1, 
some samples were not repeated more than n = 2. Permeability values could not be determined 
for peptides 29, 30 and 31 due to poor sample solubility. 
Retention time measurements. Samples were analyzed using RP-HPLC. A Phenomenex 
Jupiter 5 μm C18 300 Å 150 x 2 mm column was employed, with a flow rate of 0.3 mL/min at 
25°C. A solvent gradient was employed as follows: 5% B over 5 min, 5–100% B over 47.5 min 
(Solvent B was composed of 90% v/v acetonitrile, 9.95% v/v water, 0.05% TFA). An early-
eluting peptide (Ac-Pro-Glu-Glu-Leu-Gly-Leu-Asp-Gly-Lys-OH) and a late-eluting peptide 
(peptide 12) were added to each sample prior to injection. Peptide samples were dissolved in 
DMSO to a final concentration of ~0.1 mM. 
Amide temperature coefficient studies. The temperature dependence of amide proton 
chemical shifts was derived from 1D and TOCSY spectra recorded on a Bruker Avance 500 
MHz spectrometer. Spectra were measured between 288 K and 308 K, in 5 K increments, and 
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referenced to DSS at 0 ppm. Assignment of the spectra was performed using the program rNMR 
[18] and/or CCPNMR [19].  
Translational diffusion coefficient studies. Translational diffusion coefficients were 
measured as described previously [20]. Briefly, PFG-NMR spectra were acquired at 25ºC on a 
Bruker Avance 500 MHz spectrometer. Diffusion coefficients were measured by incrementing 
either the duration of the field gradient pulses or the amplitude while the separations of the field 
gradients and the total echo time remained constant. 
Quantitative Structure Activity Relationship (QSAR) studies. QSAR analyses were 
performed using an in-house spreadsheet embedded with QSAR routines. Prior to fitting, the 
descriptor values were auto-scaled by subtracting the mean and dividing the resultant values by 
the standard deviation. 
Molecular Dynamics Analysis. Cyclic hexapeptides were generated using CYANA [21] 
using only cis/trans peptide bond constraints (identified from the NMR spectra) producing 20 
low energy conformers/peptide. Structures with near identical conformations were removed from 
the pools, resulting in 4–10 unique conformations per peptide. The peptides were solvated in 
30% acetonitrile using YASARA v.13.9.8 [22] and produced systems of 600–700 TIP3 water 
and 100–150 acetonitrile molecules. Simulation topology files were prepared using VMD 1.9.1 
[23] and the CHARMM27 topologies. For acetonitrile the CGenFF 2b8 topology [24] was used, 
whereas custom topologies for N-methylated amino acids were constructed using SwissParam 
[25].  
Each solvated peptide was equilibrated using a stepwise relaxation procedure. In the first 
stage, all heavy-atoms were harmonically restrained with a force constant of 2 kcal/(mol Å2) 
before a conjugate gradient minimization of 500 steps was applied using NAMD 2.9 CUDA [26] 
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and CHARMM27 force field parameters. N-methyl parameters were constructed as described for 
topologies above. This was followed by heating to 298 K before simulating 500 ps under NPT 
conditions with periodic boundary conditions. A Langevin thermostat with a damping coefficient 
of 0.5 ps-1 was used to maintain the system temperature. The system pressure was maintained at 
1 atm using a Langevin piston barostat. The particle mesh Ewald algorithm was used to compute 
long-range electrostatic interactions at every time step and non-bonded interactions were 
truncated smoothly between 10 Å and 12 Å. All covalent hydrogen bonds were constrained by 
the SHAKE algorithm (or the SETTLE algorithm for water), permitting an integration time step 
of 2 fs. For the second stage of 1 ns, the restraints were retained on α-carbons (Cα) only, whereas 
all constraints were released in the third stage of 1 ns. Production runs were simulated for 10 ns 
while saving 10,000 evenly spaced frames for each simulation. 
The hydrogen bond patterns during the last equilibration trajectory step determined using the 
HBonds Plugin v. 1.2 in VMD (bond lengths and angles set to 3.3 Å and 40°, respectively). The 
bond angle was chosen based on a study of over 4,500 protein crystal structures which found that 
over 80% of protein backbone 𝑁𝑁𝑁𝑁 − 𝑂𝑂 hydrogen bonds fall within a < 40° cut-off [27]. The 
conformation variant of each peptide that most closely aligned with temperature coefficients 
determined by NMR was selected for production runs. As the starting structures of the peptides 
were based on experimentally-derived data, we did not expect substantial conformational 
changes to occur and chose to conduct production runs of 10 ns. Subsequent hydrogen bond 
analysis were performed for all saved frames and peptides as described above. The biophysical 
properties and Cα RMSD variations of peptides were determined using VEGA ZZ v. 3.0.2.48 
[28] (Probe radius 1.4 Å; resolution 10; 10,000 frames per peptide) and MUSTANG [29] in 
YASARA respectively. The average peptide simulation structures from the production 
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trajectories in 30% acetonitrile were solvated in chloroform, parameterized, equilibrated, 
simulated and analyzed as described above. 
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RESULTS 
Design and synthesis of cyclic hexapeptides. The sequences of the cyclic peptides 
synthesized for this study are detailed in Figure 2, and are divided into three groups. Group 1 
contains cyclic hexapeptides with the general sequence, cyclo(Leu-Leu-Leu-Leu-Pro-Tyr), but 
have varied chirality and N-methylation configurations, and therefore are expected to have 
varied conformations. Some of these peptides have been reported to have high in vitro and in 
vivo permeability; peptides 12 (referred to as 1 in [14]) and 13 (referred to as 15 in [15]), for 
example, both displayed oral bioavailability greater than 20%, which is unusually high for 
peptides. Group 2 comprises peptides with a similar range of chirality and N-methylation 
configurations as those in Group 1, but was designed to explore the effect of sequence variation 
on peptide permeability. Group 3 contains cyclic hexapeptides with a greater range of sequence 
variation compared to Group 2, and are mainly derived from the orbitides – a family of naturally-
occurring cyclic peptides from plants [30]. These peptides were included in this study to examine 
the potential permeability of naturally-occurring cyclic peptides. In total, we examined 62 
different cyclic hexapeptides to begin exploring experimental and computational markers of 
peptide permeability. 
In vitro permeability studies. We analyzed the membrane permeability of our suite of cyclic 
peptides across a Caco-2 cell monolayer (Supplementary Table 1), a cell-based system that 
incorporates both active and passive transport mechanisms. Similarly, we assessed the 
permeability of our peptides using PAMPA (Supplementary Table 1), which is used to determine 
the passive membrane permeability of analytes through an artificial phospholipid membrane and 
correlates well to in vivo absorption rates [31]. We observed a positive correlation between 
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Caco-2 and PAMPA permeability (r2 = 0.72), as shown in Figure 3, suggesting that the cyclic 
peptides in this study mostly engage in passive transport pathways. 
HPLC capacity factor as a predictor of permeability. Measurement of retention times is a 
rapid and convenient way to probe the surface properties of an analyte, and has recently been 
used to study the surface hydrophobicity of cyclic alanine-rich peptides [9]. In fact, retention 
time measurements converted to their respective capacity factors (and more specifically the 
logarithm of the capacity factors, log k') have been widely used as a method for estimating 
lipophilicity [32]. To begin exploring experimental markers, we first correlated the retention 
times of the peptides on reversed-phase high performance liquid chromatography (RP-HPLC) to 
their observed Caco-2 and PAMPA permeability, as shown in Figures 4A and 4B, respectively, 
as well as to their recovery from the permeability assays, as shown in Supplementary Figure 1. 
Figure 4C shows a typical RP-HPLC chromatogram acquired using acetonitrile as the organic 
component of the mobile phase; for each sample, we added an early-eluting and a late-eluting 
peptide to calibrate measurements between samples. We then calculated the capacity factors (as 
log k'; Supplementary Table 2) and correlated them to their Caco-2 and PAMPA permeability, as 
shown in Figures 4D and 4E, respectively. Noticeably, there is a positive correlation between log 
k' and the logarithm of the apparent permeability value measured using the Caco-2 assay (r2 = 
0.75; Figure 4D). For the PAMPA result shown in Figure 4E, permeability of the cyclic peptides 
also increases with increasing log k' (r2 = 0.77 for log k' ≤ 1.3). In contrast, the correlation 
appears to invert for log k' > 1.3; although the correlation is weak (i.e. r2 = 0.32), this behavior 
would be consistent with that reported for hydrophobic compounds that passively diffuse across 
a artificial membranes [33,34]. Nevertheless, the apparent dependence of cyclic peptide 
permeability on log k' suggests that the capacity factor (or, in principle, retention time) can be 
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used as a 'filter' to guide the design of membrane-permeable peptides. More specifically, peptides 
that eluted before 30 min (or had a log k' less than approximately 1.23) showed very low 
permeability (Figures 4A, 4B, 4D and 4E). Interestingly though, not all peptides that eluted after 
30 min displayed high permeability in both Caco-2 (Figure 4A) and PAMPA (Figure 4B) assays, 
inspiring us to search for other experimental markers that might explain the differences in the 
observed rates of peptide diffusion across membranes. 
Amide temperature coefficients and hydrogen bonding potential as predictors of 
permeability. To clarify whether the hydrogen bonding potential of peptides affects their in vitro 
permeability, we examined basic properties of the peptides that could be easily ascertained from 
their representative chemical structures, such as the number of hydrogen bond donors, hydrogen 
bond acceptors and N-methylated amides. Although some of these properties have been used to 
guide the design of small-molecule therapeutics, we found no clear correlation between any of 
these properties and the permeability of the peptides (Supplementary Figure 2). We reasoned that 
since the solution conformation will have a different number of 'available' hydrogen bond donors 
and acceptors to that predicted based on their two-dimensional chemical representation, 
experimental measurement of the hydrogen bonding potential of the peptides would be a more 
useful and meaningful biomarker of peptide permeability. 
To do this, we investigated the utility of NMR chemical shift temperature coefficients 
(∆δNH/∆T), which are non-destructive and convenient measures of the hydrogen bond network of 
a protein/peptide [35]. It has been proposed that backbone amides with very negative ∆δNH/∆T 
(i.e. < -4.6 ppb/K) are solvent-exposed, whereas those with less negative or slightly positive 
∆δNH/∆T (i.e. ≥ -4.6 ppb/K) are considered to be involved in intra-molecular hydrogen bonds 
[36]. Panels A and B of Figure 5 show the ∆δNH/∆T for each amide of peptides 1 and 5, 
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respectively, in 30% v/v acetonitrile. We measured ∆δNH/∆T values for all 62 peptides and used 
these values to predict the number of intra-molecular hydrogen bonds for each peptide. However, 
there was no clear correlation between permeability and the combined number of intra-molecular 
hydrogen bonds and N-methyl groups, though a positive trend was emerging for permeability 
values measured using the Caco-2 assay (Supplementary Figure 3). It is worth noting that the 
cut-off value of -4.6 ppb/K used in our analysis was proposed based on a study of proteins in 
water [36] and may not be appropriate for the small cyclic peptides in this study, which were 
dissolved in a buffer containing a percentage of organic solvent (though we investigate this issue 
in more detail later using molecular dynamics simulation). Nevertheless, we wondered whether 
the strength of each hydrogen bond might also be an important consideration. 
Based on the above observations, we propose the Ʃ∆δNH/∆T value as a convenient overall 
measure of the hydrogen bonding potential of a peptide; examples of this value for peptides 1 
and 5 are shown in Figure 5A and 5B, respectively. In addition to calculating Ʃ∆δNH/∆T values 
for the peptides in 30% v/v acetonitrile, we further explored the utility of other solvent systems, 
i.e. 100% v/v acetonitrile, 100% v/v chloroform, 10% v/v DMSO with 90% chloroform and 
100% v/v DMSO, measuring ∆δNH/∆T values for peptides from Group 1. We focused on Group 
1 peptides because they were late-eluting but still showed varied permeability. Supplementary 
Figure 4 shows the Ʃ∆δNH/∆T values plotted against Caco-2 and PAMPA permeability. 
Although a definitive correlation was not observed, a general relationship for some cases 
emerged, as shown in left panel of Supplementary Figure 4C. Overall, these results encouraged 
us to investigate more sophisticated ways of utilizing Ʃ∆δNH/∆T values. 
An experimental model of peptide permeability. We hypothesized that rather than 
assessing each parameter by itself, a combination of experimental parameters would provide 
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more insight into the physico-chemical properties affecting peptide permeability. Indeed, 
analysis of the Caco-2 permeability of our peptides using the Quantitative Structure-Activity 
Relationship (QSAR) procedure showed that we could improve the agreement between observed 
and calculated log Papp-caco by incorporating both log k' and Ʃ∆δNH/∆T values in the calculation 
(Supplementary Table 4). For example, using log k' alone in the calculations resulted in a r2 of 
0.62, and using Ʃ∆δNH/∆T values from samples in 30% v/v acetonitrile or 10% v/v DMSO, 90% 
v/v chloroform alone resulted in r2 values of 0.22 or 0.15, respectively; whereas, using both input 
types resulted in an improvement in r2 values, i.e. 0.64 and 0.70 for the combined use of log k' 
and Ʃ∆δNH/∆T values for the two different solvent conditions mentioned above, respectively. An 
equation describing the permeability of Group 1 peptides can be formulated as follows: log𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎−𝑐𝑐𝑎𝑎𝑐𝑐𝑐𝑐 = 0.54(±0.08) log 𝑘𝑘′ + 0.21(±0.08)Ʃ∆δNH/∆T − 0.55(±0.08)  
𝑛𝑛 = 28, 𝑠𝑠 = 0.41, 𝑟𝑟2 = 0.70, 𝑞𝑞2 = 0.63 
where n is the number of cyclic peptides, s is the standard error, r the correlation coefficient, q 
the cross-validated (leave-one-out) correlation coefficient, and the figures in parentheses are the 
standard error values for the coefficients or the constant. Similarly, QSAR analyses of the 
PAMPA permeability coefficients showed that using both log k' and Ʃ∆δNH/∆T values provided 
more accurate predictions of log Papp-pampa (Supplementary Table 4). For example, using log k' or 
Ʃ∆δNH/∆T values (10% v/v DMSO, 90% v/v chloroform) alone in the calculations resulted in a r2 
of 0.05 and 0.24, respectively; however, using both molecular descriptors gave a r2 of 0.57. Of 
the different solvent systems used to measure Ʃ∆δNH/∆T values, 100% v/v chloroform provide 
the best correlation in combination with log k', with a r2 of 0.68. This is interesting because 
chloroform is a weak hydrogen bond acceptor and is thus expected to have a relatively small 
effect on the proton resonance of solvent-exposed amides compared to strong hydrogen bond 
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acceptors like DMSO. Perhaps the potential utility of chloroform as the solvent system for 
temperature coefficient measurements reflects its ability to mimic the interior of the lipid bilayer.  
We also carried out a bilinear analysis to model the negative impact of high log k' values on 
permeability, as exemplified in a study on the PAMPA permeability of hydrophobic compounds 
[33,34]. In general, the correlation was further improved using this type of analysis, resulting in 
equations similar to the following: log𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎−𝑎𝑎𝑎𝑎𝑝𝑝𝑎𝑎𝑎𝑎= 3.10(±1.42) log 𝑘𝑘′ + 0.24(±0.06)Ʃ∆δNH/∆T
− 2.84(±1.42) log�β10logk′ + 1� − 0.08(±0.06)  
𝑛𝑛 = 26, 𝑠𝑠 = 0.30, 𝑟𝑟2 = 0.63, 𝑞𝑞2 = 0.52 
where the Ʃ∆δNH/∆T values, in this example, are measured using 10% v/v DMSO, 90% v/v 
chloroform, and  log𝛽𝛽 = −2.32, as suggested in a previous study [33]. Here, cyclic peptides 12 
and 16 were omitted from the analyses because their low recoveries (i.e. < 50%; Supplementary 
Figure 1) would affect the accuracy of their observed permeability. Regardless of the type of 
QSAR model applied, the QSAR analyses performed herein demonstrate that both molecular 
descriptors, i.e. HPLC capacity factor and amide temperature coefficients, contribute to cyclic 
peptide permeability. 
 In addition to quantitative analyses, we carried out qualitative analyses of our permeability 
data. Figures 5C, 5D and Supplementary Figure 5 show the relationship between permeability 
(divided into four levels depending on the permeability value), retention time, and Ʃ∆δNH/∆T 
measured in four different solvent systems. Strikingly, the combination of retention time and 
Ʃ∆δNH/∆T value was generally able to resolve peptides with high permeability from peptides 
with low permeability, particularly for permeability measured using the Caco-2 assay, but this 
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was not as noticeable for permeability measured by PAMPA. Specifically, peptides with very 
high permeability have high retention times and less negative Ʃ∆δNH/∆T values, whereas 
peptides with very low permeability have low retention times or very negative Ʃ∆δNH/∆T values, 
as shown in the left-hand panels of Figures 5C and D. 
Molecular simulations of peptide conformations in explicit solvent. To understand the 
molecular forces underpinning the observed relationship between retention time, Ʃ∆δNH/∆T 
values and permeability, we conducted molecular dynamics simulations of the peptides in 
explicit solvent (Figure 6A) and monitored their molecular motion over 10 ns after an initial 
equilibration period. To validate our simulated structures we compared parameters measured in 
silico with parameters measured in vitro (Figures 6 and 7). A positive correlation was observed 
between vLogP, an estimate of the n-octanol/water partition coefficient calculated from the 
peptide structures simulated in 30% v/v acetonitrile, and retention time (r2 = 0.70; Figure 6B), 
providing confidence in our computational method. We then measured surface properties of the 
peptides from their tertiary structures over the course of the simulation (Figure 6C) and observed 
a stronger correlation between total hydrophobic surface area and retention time (r2 = 0.63) than 
total polar surface area and retention time (r2 = 0.29). 
As ∆δNH/∆T values have been used to predict hydrogen bonded amides within proteins, we 
investigated whether we could observe a relationship between ∆δNH/∆T and the presence of a 
hydrogen bond within our peptides. Over the course of a molecular dynamics simulation for each 
peptide, we measured the frequency of each amide participating in an intra-molecular hydrogen-
bond. Although amides frequently participating in an intra-molecular hydrogen-bond tended to 
have less negative ∆δNH/∆T values (Supplementary Figure 6A), a more prominent relationship 
was observed between ∆δNH/∆T and the frequency of an amide participating in inter-molecular 
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hydrogen bonds with solvent molecules (Figure 7A and Supplementary Figure 6B). Specifically, 
amides with very negative ∆δNH/∆T values were frequently involved in hydrogen bond 
interactions with solvent, whereas amides with less negative ∆δNH/∆T values were infrequently 
involved in solvent interactions. Interestingly, a strong correlation was observed between the 
Ʃ∆δNH/∆T values and the total frequency of all amides participating in solvent hydrogen-bonds 
for each peptide (r2 = 0.81; Figure 7B) and the total solvent-exposed surface area of the amide (r2 
= 0.69; Supplementary Figure 6D). Overall, these results provide a structural basis for the 
measured ∆δNH/∆T values. 
We also carried out molecular dynamics simulations of the peptides in 100% v/v chloroform 
and 10% v/v DMSO with 90% v/v chloroform, and the results are summarized in Supplementary 
Figure 7. In general, the overall conformation of the peptides remained similar across different 
solvents as shown in Supplementary Figure 8, which is consistent with the idea that the cyclic 
backbone constrains the conformation of the peptides. 
A computational model of peptide permeability. As a combination of experimental 
parameters was useful in resolving the physico-chemical properties of peptides that relate to 
permeability, we tested whether multiple computational parameters could also provide insight 
into the factors affecting peptide permeability. Supplementary Figure 9 shows the relationship 
between vLogP, total solvent hydrogen bond frequency and permeability, as well as total 
hydrophobic surface area, total polar surface area and permeability. Peptides with high 
permeability tend to have high partition coefficients and few hydrogen bond interactions with 
water (Supplementary Figure 9). Additionally, peptides with high permeability tend to have 
solvent exposed surfaces with larger hydrophobic and smaller polar content (Supplementary 
Figure 9).  
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DISCUSSION 
There is an increasing focus in the pharmaceutical industry on the development of oral 
peptide therapeutics. In this study, we explored experimental and computational measures of 
peptide permeability to help guide medicinal chemists during peptide-based drug design. We 
assembled a library of 62 cyclic hexapeptides with varied in vitro permeability and, based on a 
systematic analysis of experimental markers, we developed a model that helps to explain the 
different permeability efficiencies of these peptides. Furthermore, we provided insight into the 
fundamental structural features described by the experimental biomarkers using molecular 
dynamics simulations in explicit solvent. We note that the results described herein relate 
primarily to passive transport of peptides across a cell barrier. 
Initially we searched for a single experimental biomarker of peptide permeability. We found a 
striking relationship between the HPLC capacity factor and in vitro permeability (Figure 4). We 
then found a correlation between the capacity factor and the predicted lipophilicity, suggesting 
that lipophilicity is an important determinant of peptide permeability. Lipophilicity is important 
likely because passive diffusion through the hydrophobic core of the lipid bilayer, which is a 
major constituent of the cell membrane, is promoted by increased peptide lipophilicity. This 
observation is consistent with previous observations for small molecules [3], indicating that 
lipophilicity is a general property that affects permeability. Analysis of surface properties of 
simulated structures revealed that the retention times were also related to the surface 
hydrophobicity of the cyclic peptides (Figure 6), which is consistent with studies on linear 
peptides and their retention times [37]. This correlation suggests that the total surface area of 
exposed hydrophobic atoms/residues is related to peptide lipophilicity and affects peptide 
permeability. Indeed, increasing the hydrophobicity of peptide 1 (retention time of 32.4 min) by 
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replacing Tyr-6 with a Trp residue to produce peptide 23 (retention time of 35.4 min) resulted in 
a 7-fold increase in permeability across Caco-2 cells. Despite this finding, we observed that 
many peptides with high retention times still displayed poor permeability, suggesting that 
lipophilicity in isolation is not a sufficient descriptor of peptide permeability. In our experience, 
increasing lipophilicity alone as a strategy is detrimental to the delivery of orally efficacious 
drugs because it negatively impacts properties like solubility and metabolic stability; therefore, it 
is important to explore other properties that may impact bioavailability. 
Looking beyond lipohilicity, we then considered the hydrogen bonding potential of the 
peptides following recent literature reports on the importance of intra-molecular and inter-
molecular hydrogen bonds for cyclic peptides [14-16] and small molecules [38]. Specifically, 
structural studies of cell-permeable peptides have suggested that steric occlusion of polar groups 
and internal hydrogen bonding can lead to increased permeability [39,40]. Recognizing that 
hydrogen bonding potential is heavily dependent on conformation, we explored whether 
structural tools that can experimentally probe the hydrogen bond network can also be used as 
biomarkers of peptide permeability. We focused on amide temperature coefficients instead of 
hydrogen-deuterium exchange rates because amide temperature coefficients are easily measured 
in different solvent systems (i.e. composition and pH) and do not require temporal monitoring of 
the kinetics, though both techniques have been widely used to provide supplemental information 
on protein structure. Additionally, we were encouraged by our recent study, in which we showed 
that amide temperature coefficients could be used to guide the design and synthesis of N-
methylated cyclic peptides that had small-molecule-like oral bioavailability [15]. Our previous 
study was based on the hypothesis that amide temperature coefficients could be used to identify 
appropriate amides for chemical modification. In this study, we showed, using molecular 
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dynamics simulations, that amide temperature coefficients are a measure of the relative solvent 
exposure of amides (Figure 7). Therefore, modification of exposed amides with N-methyl groups 
effectively caps these amides, reducing hydrogen bond interactions between the solvent and the 
peptide. However, in this study, we also found that peptides with similar hydrogen bonding 
potential could still display very different levels of permeability. For example, peptide 16 and 42 
have the same N-methylation pattern (i.e. amides of residues 1, 2 and 4 were modified) and 
hydrogen bond network but the Caco-2 permeability of 16 is significantly higher than that of 42. 
Therefore, hydrogen bonding potential alone is not a sufficient descriptor of peptide 
permeability. 
We therefore considered the effect of both lipophilicity and hydrogen bonding potential on 
peptide permeability. Indeed, quantitative analyses of the permeability coefficients showed that 
both molecular descriptors contributed to permeability. On the basis of this result and our 
qualitative analyses, we propose our first model of peptide permeability based on experimentally 
measured parameters, as shown in Figure 8A. Specifically, peptides with the highest 
permeability have high lipophilicity and few solvent interactions, whereas peptides with the 
lowest permeability have poor lipophicility or many solvent interactions. The permeability of 
peptides with a moderate number of solvent interactions can be improved by increasing its 
lipophilicity, which would partly compensate for the presence of unfavorable solvent 
interactions. The comparison of peptides 1 and 23 mentioned above is an example of this 
scenario. Similarly, the permeability of peptides with moderate lipophilicity can be improved by 
reducing the number of its hydrogen bond interactions with solvent. For example, the 
permeability of peptide 1 was improved by N-methylating its exposed amides to produce peptide 
13. It is worth noting that in some cases these two markers are related. For example, addition of 
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N-methyl groups at appropriate locations not only reduces the number of solvent interactions but 
also increases lipophilicity (by increasing surface hydrophobicity).  
Our first model can be applied to explain the derived correlations using Caco-2 permeability 
values (Figures 5C and 5D, leftmost panels). The same trend is not as evident from correlations 
derived using PAMPA permeability values (Figures 5C and 5D, rightmost panels), where 
peptides with the highest lipophilicities and fewest solvent interactions were not the most 
permeable. In fact, after a certain threshold, increasing lipophilicity appeared to be detrimental to 
permeability (Figure 4E). We reason that an additional parameter is affecting our observed 
trends, namely solubility. With regard to peptides, increasing the lipophilicity would be expected 
to reduce solubility, as suggested recently [41] and as seen with small molecules [42], and 
thereby affect permeability. This is probably because increased lipophilicity might lead to 
peptide aggregation or sequester the peptides in the lipid membrane due to less favorable 
interactions in the aqueous phase. Indeed, this reduced solubility is reflected in the recovery 
rates, as shown in Supplementary Figure 1. Increased lipophilicity leads to lower recovery rates; 
this effect is more pronounced for PAMPA measurements compared to Caco-2 measurements. 
Therefore, we propose our second model, shown in Figure 8B, which defines an 'island of 
permeability' (shown in white). Peptides with lipophilicity and solvent interactions that lie on 
this 'island' are likely to have high permeability. This plot has similarities to the 'golden triangle' 
discussed by Johnson and colleagues [43], which focused on lipophilicity and molecular weight 
of small molecules. 
We can rationalize our model using principles of thermodynamics. For peptides to permeate 
across a lipid bilayer, they must first insert into the bilayer; in other words, they must transition 
from one environment type, i.e. an aqueous environment with a high dielectric constant, to 
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another, i.e. the bilayer core that would have a low dielectric constant. The principles underlying 
this transfer between two different environments is analogous to studies on partition of 
molecules between two different solvents [44]. For peptides, it has been proposed that the free 
energy of insertion (ΔGI) of cyclic peptides into a lipid bilayer is strongly correlated to the 
logarithm of the PAMPA permeability coefficient. Additionally, it has been proposed that the 
transfer free energy is affected by the solvation free energy (ΔGsolv) [45], which describes 
changes in the solvation of the cyclic peptides upon partitioning and is composed of electrostatic 
contributions and non-polar contributions. Electrostatic contributions result from changes in the 
solvent dielectric constant and is affected by the peptide hydrogen bond network. As an example, 
the cost of transferring isolated 𝐶𝐶 = 𝑂𝑂 and 𝑁𝑁 − 𝑁𝑁 groups would be greater compared with a 
single hydrogen bond 𝐶𝐶 = 𝑂𝑂 ∙∙∙ 𝑁𝑁 − 𝑁𝑁. Non-polar contributions, or otherwise known as the 
classical hydrophobic effect, accounts for van der Waals and solvent structure effects. Although 
hydrophobicity can drive insertion of peptides into the lipid bilayer [45] it will also lead to 
decreased solubility in response to the cohesive energy of water [46]. As the lipid bilayer is a 
complex biomolecular system, it is likely that other energy-terms are also important, including 
lipid perturbation effects and contributions from peptide conformational changes. 
The work described here provides a basis for future studies examining other features of 
peptides that might affect permeability, such as those proposed to affect small molecule 
permeability. Since Lipinski's seminal work [2], many features affecting small molecule 
permeability have been reported, including the ionization state [47,48], and molecular size and 
shape [3,43], which we have not considered in our study and thus there will be limitations to our 
model. We anticipate that our 'island' may shift for peptides with larger molecular weights than 
those used in this study. As reported for small molecules, an increased lipophilicity is required to 
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obtain sufficient oral uptake as molecular weight increases [42]. A disadvantage of increasing 
lipophilicity of small molecules is that increased lipophilicity is known to be correlated to higher 
levels of target promiscuity [49], as well as increased risks of in vivo animal toxicity [50]. We 
speculate that structurally more complex macrocyclic peptides might enable increased 
selectivity, and therefore, the risks of increased lipophilicity could be lower than for oral small 
molecule drugs. Another encouraging observation is that the molecular weight of the cyclic 
peptide cyclosporine A, which is administered orally as an immunosuppressant, is above 1000 
Da, signifying that oral bioavailability can be achieved for peptides with molecular weights 
beyond those studied here.  
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CONCLUSION 
We have investigated the physico-chemical properties of cyclic peptides that relate to 
permeability. We focused on the effect of lipophilicity and solvent interactions and proposed an 
'island of permeability' to help understand the features of peptides that contribute to their cell 
permeability and potential orally bioavailability. We employed experimental techniques that are 
fast and convenient, recognizing the need for such methods in high-throughput drug design. We 
focused on molecular dynamics simulations to try and obtain accurate in silico models, though 
we expect that more rapid computational methods would also prove useful. Although it remains 
to be seen whether macrocyclic peptides will define a novel space of oral therapeutics, there are 
already encouraging signs from clinical drugs and candidates. A recent survey of macrocyclic 
drugs [51], of which macrocyclic peptides form a sub-class, revealed that 28% of registered 
macrocycles are delivered orally and 43% of clinical candidates are intended for oral 
administration. Although the examples of orally administered macrocyclic peptide drugs are still 
rare, we anticipate that more examples will be discovered and validated in the near future. 
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Figure Captions 
Figure 1: Markers of peptide permeability across a membrane. Using computational and 
experimental tools, we examined various physico-chemical properties of peptides, e.g. their 
lipophilicity and hydrogen bonding potential, and correlated these properties to membrane 
permeability. A stick and surface representation of the predicted structure of a cyclic hexapeptide 
studied in this work is shown; carbon atoms are colored orange, oxygen atoms are shown in red, 
and nitrogen atoms are colored blue. 
 
Figure 2: Cyclic peptides studied in this work. The peptides are divided into three groups: 
Group 1 (Leu-rich), Group 2 (sequence variants) and Group 3 (orbitide-like), based on their 
amino acid composition. Each peptide's sequence is shown in three-letter code. N-methylated 
residues are indicated using grey shading. A chemical representation of peptide 1 is shown in the 
bottom left of the figure. 
 
Figure 3: Relationship between apparent permeability (Papp-caco) measured using the Caco-2 
assay and apparent permeability (Papp-pampa) measured using PAMPA. The peptides used in 
this study are divided into three groups, defined in Figure 2. The symbols of the three groups are 
shown in the inset; an empty circle belongs to Group 1 but represents peptides that have a 
recovery of less than 50% (see Supplementary Figure 1). Logarithm values are shown as mean ± 
standard error of the mean. A linear correlation was fitted to permeability values (except for 
those with low recovery) is shown as a dotted line. The measured values are shown in 
Supplementary Table 1. 
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Figure 4: Retention times of peptides as a marker of peptide permeability. Relationship 
between retention time measured using RP-HPLC and (A) apparent permeability (Papp-caco) 
measured using the Caco-2 assay or (B) apparent permeability (Papp-pampa) measured using 
PAMPA. The peptides are divided into three groups, defined in Figure 2. The symbols of the 
three groups are shown in the inset in panel A; an empty circle belongs to Group 1 but represents 
peptides that have a recovery of less than 50% (see Supplementary Figure 1). Values are shown 
as mean ± standard error of the mean. C) A typical RP-HPLC chromatogram used to measure the 
retention time of peptides (see Supplementary Information for traces of each peptide). Two 
internal standards were included in each run, an early-eluting and a late-eluting peptide (details 
in Methods). The peak of an example test peptide is shaded grey. A small peak eluting at ~30 
min was observed, and is from an impurity from the DMSO used to dissolve the peptide samples, 
and not from the peptide synthesis and purification process (details in Supplementary Results). 
The gradient (i.e. percentage of 90% v/v acetonitrile, 9.95% v/v water, 0.05% v/v TFA) used is 
shown as a dotted line. Relationship between the logarithm of the HPLC capacity factor (log k') 
and (D) the logarithm of Papp-caco or (E) Papp-pampa. A bilinear analysis was carried out for the 
PAMPA results; an r2 of 0.77 was obtained for log k' ≤ 1.3 and an r2 of 0.32 for log k' > 1.3. The 
shaded region in (E) represents the region with log k' > 1.3. The capacity factors for the cyclic 
peptides are shown in Supplementary Table 2. 
 
Figure 5: Relationship between retention time, amide temperature coefficients, and 
permeability. A) Chemical structure of peptide 1 with the ∆δNH/∆T values in 30% v/v 
acetonitrile for each amide indicated. B) Chemical structure of peptide 5 and the ∆δNH/∆T values 
in 30% v/v acetonitrile. The summation of all ∆δNH/∆T values (Ʃ∆δNH/∆T) is shown for each 
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peptide. Correlative plots for Ʃ∆δNH/∆T derived from 30% v/v acetonitrile, and 10% v/v DMSO 
with 90% v/v chloroform are shown in panels (B) and (D), respectively. In each panel, the 
leftmost plot corresponds to Caco-2 permeability measurements and the rightmost plot 
corresponds to PAMPA permeability measurements. Both apparent permeability (Papp) measured 
using the Caco-2 assay (left panels) and percent permeability (%P) measured using PAMPA 
(right panels) are divided into four levels depending on their mean permeability values, as 
indicated in the key at the bottom of the figure. Empty circles represent peptides that have a 
recovery of less than 50% (see Supp. Figure 1). 
 
Figure 6: Validation of molecular dynamics simulations of peptides. A) Peptides were 
subjected to molecular dynamics simulations in a defined box of explicit solvent. B) Correlation 
between observed retention time and calculated vLogP. C) Relationship between retention time 
and total hydrophobic surface area. Values of vLogP and total hydrophobic surface area are 
shown as mean ± standard deviation of all frames (10,000 frames) over the course of the 
production simulation. 
 
Figure 7: Relationship between hydrogen bonding potential and NMR amide temperature 
coefficients. A) Relationship between ∆δNH/∆T and the total frequency of inter-molecular 
solvent hydrogen bonds for all amides of each peptide. The amides are divided into two 
categories according to their ∆δNH/∆T value. The box-plot (5-95 percentile) shows the 
distribution of the solvent hydrogen bonding frequency within each category. B) Relationship 
between Ʃ∆δNH/∆T and the total frequency of intra-molecular hydrogen bonds for all amides of 
each peptide. 
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Figure 8: An illustrative model for peptide permeability. A) Increasing lipophilicity and 
decreasing solvent interactions of peptides can lead to peptides with high absorption. Circles of 
different colors and sizes are used to represent different permeability levels (inset); peptides with 
the highest permeability are shown as red circles, whereas peptides with the lowest permeability 
are shown as black circles. This model can be applied to the correlations derived using our Caco-
2 data (Figure 5). B) In practice, increasing lipophilicity results in peptides with poor solubility, 
resulting in poor apparent permeability. The region in white defines an 'island of permeability', in 
which peptides are likely to have high permeability. 
 
